Meeting
2018 ASCO Annual Meeting
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.
Authors
Sara A. Hurvitz
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
Sara A. Hurvitz , Paul Wheatley-Price , Debu Tripathy , Yen-Shen Lu , Louis Chow , Thomas Denis Bachelot , Roberto Hegg , Stephen K. L. Chia , Denise A. Yardley , Oliver Kong , Jahangir Alam , Ivan Diaz-Padilla , Johan Baeck , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02278120
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1047)
DOI
10.1200/JCO.2018.36.15_suppl.1047
Abstract #
1047
Poster Bd #
128
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
First Author: Yen-Shen Lu
Poster
2023 ASCO Annual Meeting
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
First Author: Nagi S. El Saghir
Poster
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
First Author: Ryan Tooker
Poster
2021 ASCO Annual Meeting
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
First Author: Seock-Ah Im